Almac Discovery's current official pipeline lists an oral GSPT1 molecular glue and a GSPT1 degrader–antibody conjugate, both preclinical. DAC payloads are used in HER2/CD33-targeted constructs.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Almac Discovery's current official pipeline lists an oral GSPT1 molecular glue and a GSPT1 degrader–antibody conjugate, both preclinical. DAC payloads are used in HER2/CD33-targeted constructs.
Program / service
Target / indication
Representative stage
Evidence & scope
GSPT1 Molecular Glue Degrader
GSPT1 · See individual trial / indication; not individually confirmed in this review
Preclinical
Human data not supported by this source
GSPT1 Degrader Antibody Conjugate
GSPT1 payload / HER2, CD33 delivery · See individual trial / indication; not individually confirmed in this review
Preclinical
Preclinical; in vivo evaluation ongoing (company-reported)
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
DUB inhibitors such as USP7 inhibitors are not automatically protein degraders. General group CMC services do not establish that this division offers external TPD discovery services.
